News
ESDR2026 confirmed keynotes speakers
Dear Colleagues, dear Friends, We are delighted to announce that our keynote speakers and...
2026 abstracts submission is open
Dear colleague, We are pleased to announce that abstract submission for the 55th Annual ESDR...
Women in Science by ESDR
This 11 February, on the International Day of Women and Girls in Science, ESDR launches Women in...
Become a Social Media Ambassador for ESDR2026
We are excited to announce an opportunity to become a Social Media Ambassador for the 55th Annual...
Join the ESDR Board in 2026
Applications are now open to serve on the ESDR Board from October 2026. 3 positions are available....
FLA Legacy: celebrating our future leaders
We’re excited to launch a new storytelling series spotlighting the achievements of Future Leaders...
About The ESDR
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of over 1200.
By supporting investigative dermatology, the ESDR contributes towards improving the health of patients suffering from skin and venereal disease. Applications of recent scientific advances have produced diagnostic and therapeutic innovations in dermatological practice, particularly in genetics, skin cancer, allergic skin disease, infectious disease and autoimmune diseases.
ABOUT JID
The Journal of Investigative Dermatology (JID) is the official journal of the ESDR and SID. JID publishes papers describing original research on all aspects of cutaneous biology and skin disease. Topics include biochemistry, biophysics, cell regulation, carcinogenesis, skin structure, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, physiology, pharmacology, photobiology, percutaneous absorption, clinical research, epidemiology and other population-based research.
JID Latest
- Corrigendum to ‘The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma’
- Blockade for CD276-mediated suppression of tumor-specific CTLs may contribute to achieving durable responses with immune checkpoint inhibitors
- Core outcome sets: What are they and why they matter
- Single-cell proteomics reveal lesion-specific aberrant T cells and immunological profiles in Mycosis Fungoides
- Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry.
